Interestingly, our synthetic lethality screening reveals that the small-molecule inhibition of the SMYD3 (SET and MYND domain containing protein 3; KMT3E) lysine methyltransferase potentiates alkylating agent efficacy in SCLC. The gene discussed is SMYD3; the disease is small cell lung carcinoma.